Radiation Medicine Program, Princess Margaret Cancer Centre and Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Trans-Tasman Radiation Oncology Group, University of Newcastle, Newcastle, New South Wales, Australia.
Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1096-1106. doi: 10.1016/j.ijrobp.2023.06.011. Epub 2023 Jun 29.
The TOPGEAR phase 3 trial hypothesized that adding preoperative chemoradiation therapy (CRT) to perioperative chemotherapy will improve survival in patients with gastric cancer. Owing to the complexity of gastric irradiation, a comprehensive radiation therapy quality assurance (RTQA) program was implemented. Our objective is to describe the RTQA methods and outcomes.
RTQA was undertaken in real time before treatment for the first 5 patients randomized to CRT from each center. Once acceptable quality was achieved, RTQA was completed for one-third of subsequent cases. RTQA consisted of evaluating (1) clinical target volume and organ-at-risk contouring and (2) radiation therapy planning parameters. Protocol violations between high- (20+ patients enrolled) and low-volume centers were compared using the Fisher exact test.
TOPGEAR enrolled 574 patients, of whom 286 were randomized to receive preoperative CRT and 203 (71%) were included for RTQA. Of these, 67 (33%) and 136 (67%) patients were from high- and low-volume centers, respectively. The initial RTQA pass rate was 72%. In total, 28% of cases required resubmission. In total, 200 of 203 cases (99%) passed RTQA before treatment. Cases from low-volume centers required resubmission more often (44/136 [33%] vs 13/67 [18%]; P = .078). There was no change in the proportion of cases requiring resubmission over time. Most cases requiring resubmission had multiple protocol violations. At least 1 aspect of the clinical target volume had to be adjusted in all cases. Inadequate coverage of the duodenum was most common (53% major violation, 25% minor violation). For the remaining cases, the resubmission process was triggered secondary to poor contour/plan quality.
In a large multicenter trial, RTQA is feasible and effective in achieving high-quality treatment plans. Ongoing education should be performed to ensure consistent quality during the entire study period.
TOPGEAR 阶段 3 试验假设在围手术期化疗的基础上添加术前放化疗(CRT)将改善胃癌患者的生存率。由于胃照射的复杂性,实施了全面的放射治疗质量保证(RTQA)计划。我们的目的是描述 RTQA 方法和结果。
在每个中心的前 5 例接受 CRT 随机分组的患者开始治疗之前,实时进行 RTQA。一旦达到可接受的质量,就对三分之一的后续病例进行 RTQA。RTQA 包括评估(1)临床靶区和危及器官的轮廓和(2)放射治疗计划参数。使用 Fisher 精确检验比较高(20+ 例入组)和低容量中心之间的方案违规情况。
TOPGEAR 共入组 574 例患者,其中 286 例随机接受术前 CRT,203 例(71%)纳入 RTQA。其中,67 例(33%)和 136 例(67%)分别来自高容量和低容量中心。初始 RTQA 通过率为 72%。共有 28%的病例需要重新提交。共有 203 例中的 200 例(99%)在治疗前通过 RTQA。低容量中心的病例重新提交的频率更高(44/136[33%]比 13/67[18%];P=0.078)。随着时间的推移,需要重新提交的病例比例没有变化。大多数需要重新提交的病例都有多个方案违规。所有病例都必须调整临床靶区的至少一个方面。十二指肠覆盖不足最为常见(53%主要违规,25%次要违规)。对于其余病例,重新提交过程是由于轮廓/计划质量差而触发的。
在一项大型多中心试验中,RTQA 是可行且有效的,可以实现高质量的治疗计划。应进行持续教育,以确保整个研究期间的质量一致。